Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.27 USD
−71.90 M USD
0.00 USD
23.51 M
About Mineralys Therapeutics, Inc.
Sector
Industry
CEO
Jon Congleton
Website
Headquarters
Radnor
Founded
2019
FIGI
BBG00ZXN1GN3
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MLYS is 12.60 USD — it has decreased by −2.02% in the past 24 hours. Watch Mineralys Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Mineralys Therapeutics, Inc. stocks are traded under the ticker MLYS.
MLYS stock has fallen by −6.74% compared to the previous week, the month change is a −12.92% fall, over the last year Mineralys Therapeutics, Inc. has showed a 97.80% increase.
We've gathered analysts' opinions on Mineralys Therapeutics, Inc. future price: according to them, MLYS price has a max estimate of 45.00 USD and a min estimate of 26.00 USD. Watch MLYS chart and read a more detailed Mineralys Therapeutics, Inc. stock forecast: see what analysts think of Mineralys Therapeutics, Inc. and suggest that you do with its stocks.
MLYS reached its all-time high on Feb 10, 2023 with the price of 21.98 USD, and its all-time low was 5.85 USD and was reached on Nov 22, 2023. View more price dynamics on MLYS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MLYS stock is 6.75% volatile and has beta coefficient of 2.20. Track Mineralys Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Mineralys Therapeutics, Inc. there?
Today Mineralys Therapeutics, Inc. has the market capitalization of 639.49 M, it has decreased by −10.50% over the last week.
Yes, you can track Mineralys Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Mineralys Therapeutics, Inc. is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
MLYS earnings for the last quarter are −1.13 USD per share, whereas the estimation was −0.86 USD resulting in a −30.89% surprise. The estimated earnings for the next quarter are −1.04 USD per share. See more details about Mineralys Therapeutics, Inc. earnings.
Mineralys Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
MLYS net income for the last quarter is −56.34 M USD, while the quarter before that showed −41.01 M USD of net income which accounts for −37.37% change. Track more Mineralys Therapeutics, Inc. financial stats to get the full picture.
No, MLYS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 28.00 employees. See our rating of the largest employees — is Mineralys Therapeutics, Inc. on this list?
Like other stocks, MLYS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Mineralys Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Mineralys Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Mineralys Therapeutics, Inc. stock shows the neutral signal. See more of Mineralys Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.